Loading company…
Mutabilis develops antibacterial treatments aimed at antimicrobial-resistant infections.
Founded in 2001 in France, Mutabilis develops antibacterial therapies, including dabocins and the lead programs TMR010 and TMR020 for infections caused by carbapenem-resistant Gram-negative bacteria. Pharma Omnium acquired the company from Omnes Capital in July 2009.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in